Background Prophylactic surgical treatment of the femur is commonly offered to patients with metastatic disease who have a high risk of impending pathologic fracture. Prophylactic fixation is associated with improved functional outcomes in appropriate patients selected based on established criteria, but the perioperative complication profile has received little attention. Given the substantial comorbidity in this population, it is important to characterize surgical risks for surgeons and patients to improve treatment decisions. Questions/purposes (1) What is the incidence of postoperative adverse events after prophylactic surgical stabilization of metastatic lesions of the femoral shaft or distal femur? (2) How does this complication profile compare with stabilization of pathologic fractures adjusted for differences in patient demographics and comorbidity? Methods We performed a retrospective study using the National Surgical Quality Improvement Program (NSQIP) database. We identified patients undergoing prophylactic treatment of the femoral shaft or distal femur by Current Procedural Terminology (CPT) codes. Patients undergoing treatment of a pathologic fracture were identified by CPT code for femur fracture fixation as well as an International Classification of Diseases code indicating neoplasm or pathologic fracture. We tracked adverse events, operative time, blood transfusion, hospital length of stay, and
discharge to a facility within 30 days postoperatively. There were 332 patients included in the prophylactic treatment group and 288 patients in the pathologic fracture group. Patients in the prophylactic treatment group presented with greater body mass index (BMI), whereas the pathologic fracture group presented with a greater incidence of disseminated cancer. The odds of experiencing adverse events were initially compared between the two groups using bivariate logistic regression and then using multivariate regression controlling for age, sex, BMI, and American Society of Anesthesiologists (ASA) class and disseminated cancer causing marked physiological compromise per NSQIP guidelines. Results With multivariate analysis controlling for age, sex, BMI, and ASA class, patients with pathologic fracture were more likely to experience any adverse event (odds ratio [OR], 1.53; 95% confidence interval [CI], 1.03-2.29; p = 0.036), major adverse events (OR, 1.61; 95% CI, 1.01-2.55; p = 0.043), death (OR, 1.90; 95% CI, 1.07-3.38; p = 0.030), blood transfusion (OR, 1.57; 95% CI, 1.08-2.27; p = 0.017), and hospital stay $ 9 days (OR, 1.51; 95% CI, 1.05-2.19; p = 0.028) compared with patients undergoing prophylactic treatment. However, when additionally controlling for disseminated cancer, the only difference was that patients with pathologic fractures were more likely to receive a blood transfusion than were patients undergoing prophylactic fixation (OR, 1.61; 95% CI, 1.12-2.36; p = 0.011). Conclusions After controlling for differences in patient characteristics, prophylactic treatment of femoral metastases was associated with a decreased likelihood of blood transfusion and no differences in terms of the frequency of other adverse events. In the context of prior studies supporting the mechanical and functional outcomes of prophylactic treatment, the findings of this cohort suggest that the current guidelines have achieved a reasonable balance of morbidity in patients with femoral lesions and further support the current role of prophylactic treatment of impending femur fractures in appropriately selected patients. Level of Evidence Level III, therapeutic study.
Introduction
Metastatic bone disease is a major contributor to pain, disability, and diminished quality of life in patients with cancer. When the cancer has metastasized to the femoral shaft or distal femur, the goals of treatment are to prevent pathologic fracture, reduce pain, and promote weightbearing and ambulation; surgical and nonoperative treatment modalities are available [2] . In patients who meet accepted operative indications based on the site and characteristics such as those proposed by Harrington [7] or Mirels [9] , operative fixation of the femur has been associated with decreased hospital length of stay, a lower rate of discharge to a facility, and improved functional outcomes [11, 19] . In addition, surgical fixation has been shown to prevent pathologic fracture, which can have devastating effects on survival and quality of life [4, 17] . To date, most studies of the outcomes of prophylactic fixation of the femur and other long bones have emphasized functional outcomes (eg, mobility and ROM), stability of the construct, and patient survival [3, 6, 12, 15, 18, 19] .
Although surgical fixation of the femur may offer substantial benefits to some, patients with metastatic bone disease may face high rates of both disease-and treatmentrelated complications [14, 20, 21] . Although previous studies have demonstrated acceptable functional outcomes, the profile of other postoperative complications (eg, surgical site infections, pneumonia, venous thromboembolic events) has received little attention in this population. Studies on this topic have also been limited by small sample sizes, often 20 to 100 patients [3, 6, 11, 15, 19] , limiting the ability to characterize the incidence of these relatively rare adverse events. Additionally, the focus has often been on proximal femur lesions, whereas the femoral shaft and distal femur have received considerably less attention [10, 11, 15] . Given that patients with proximal femur lesions have a different fracture risk and may experience a different complication profile than those with lesions of the diaphysis or distal femur, dedicated investigation of these more distal lesions is needed. Additionally, to our knowledge, there are no reports that compare perioperative and postoperative adverse events associated with prophylactic fixation with those after metastatic lesions that progress to a pathologic fracture. This information would better enable patients and orthopaedic oncologists to understand the potential complication profile of undergoing prophylactic fixation versus possibly having a fracture and subsequently undergoing fixation, guiding treatment selection.
Therefore, we asked: (1) What is the incidence of postoperative adverse events after prophylactic surgical stabilization of metastatic lesions of the femoral shaft or distal femur? (2) How does this complication profile compare with stabilization of pathologic fracture adjusted for differences in patient demographics and comorbidity?
Patients and Methods
A retrospective review of prospectively collected data was performed using the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database. NSQIP collects > 150 variables on patients undergoing a broad range of surgical procedures throughout the operative course at > 500 institutions throughout the United States. We selected the NSQIP database for the current study because patients are prospectively identified, reviews are performed by trained clinical reviewers with a high degree of interreviewer reliability, data are abstracted directly from the medical record and direct patient contact rather than relying on diagnostic codes, variables are clearly defined, and patients are followed to postoperative day 30 regardless of discharge status [1] .
Patients who underwent prophylactic operative stabilization of the femoral shaft or distal femur in the years 2005 to 2015 were identified by the Current Procedural Terminology (CPT) code 27495 (prophylactic treatmentnailing, pinning, plating, or wiring-with or without methylmethacrylate, femoral shaft or distal femur). Patients were excluded if they had an International Classification of Diseases (ICD) code that indicated a fracture or a primary tumor affecting the femur. We selected these fractures and the CPT code 27495 to identify a relatively uniform group of patients who underwent femoral rodding. Patients with proximal femur fractures were excluded so that no inherent differences between open reduction internal fixation and prosthetic replacement would affect the analysis. Patients who experienced a pathologic femur fracture that was surgically stabilized were identified based on an ICD code indicating pathologic fracture (733.X in ICD-9; M84.3X in ICD-10) or neoplasm (140.X-239.X in ICD-9; C or D in ICD-10) in addition to one of the following CPT codes: 27506 (treatment of femoral shaft fracture with an intramedullary implant), 27507 (treatment of femoral shaft fracture with plates/screws), or 27511/27513 (treatment of distal femur fracture).
Patient age, sex, body mass index (BMI), and American Society of Anesthesiologists (ASA) class were obtained from the NSQIP database. Additionally, the presence of "disseminated cancer" was obtained from the NSQIP. The variable is defined in NSQIP as an advanced, metastatic malignancy affecting major organs that has caused notable physiological compromise; as such, it is possible that metastatic bone disease without major organ involvement or physiological effects would not be coded as a case of "disseminated cancer" [1] . Like with other variables in the NSQIP database, it is not possible to directly confirm the accuracy of coding for the "disseminated cancer" variable or comment on the consistency of coding. However, surgical clinical reviewers who encode the variables are provided with detailed instructions including lists of positive and negative examples to promote consistent coding.
Seventeen adverse events that occurred within 30 days postoperatively were available from the NSQIP database for each patient. Major adverse events were as follows: deep surgical site infection, mechanical ventilation > 48 hours, unplanned intubation, acute renal failure, sepsis or septic shock, venous thromboembolism, stroke, cardiac arrest, myocardial infarction, return to the operating room, and death. Minor adverse events were as follows: superficial surgical site infection, wound dehiscence, pneumonia, urinary tract infection, and postoperative renal insufficiency. We regarded the occurrence of a major adverse event, minor adverse event, or readmission within 30 days postoperatively as "any adverse event." In addition, operative time $ 75th percentile (125 minutes), resulting in a blood transfusion within 72 hours postoperatively, hospital length of stay $ 75th percentile (9 days), and discharge to a nonhome facility were also recorded from the NSQIP database. All variables were defined according to NSQIP guidelines [1] .
Analysis
The prophylactic stabilization and fracture treatment groups were compared based on age, sex, BMI, ASA class, and presence of disseminated cancer. We used the chisquare test to compare categorical variables and the Student's t-test to compare continuous variables.
We determined the incidence of individual adverse events, any adverse event, major adverse event, minor adverse event, readmission, operative time $ 75th percentile, blood transfusion, hospital length of stay $ 75th percentile, and discharge to a nonhome facility. Preliminary bivariate analysis was performed using the chi-square test (see Appendix, Supplemental Digital Content 1). Of note, readmission and discharge to a nonhome facility were available only for the 2011 to 2015 editions, so only patients from these years were analyzed for those variables.
We performed two logistic regression analyses for any adverse event, major adverse event, death, minor adverse event, readmission, operative time $ 75th percentile, blood transfusion, hospital length of stay $ 75th percentile, and discharge to a nonhome facility in the fracture treatment group compared with the prophylactic stabilization group controlling for baseline differences in demographics and medical comorbidity. One regression controlled for age, sex, BMI, and ASA class. A second regression controlled for these same variables as well as disseminated cancer to isolate the role of disseminated cancer as a potential confounder. ASA class was selected to control for overall medical comorbidity in favor of a calculated measure (eg, Charlson Comorbidity Index or Elixhauser Comorbidity Index) because prior investigations have demonstrated that ASA class has a stronger or equivalent association with adverse events and lower rates of missing values in the NSQIP database [13, 16] .
All statistical tests were performed using Stata 13.1 (StataCorp LP, College Station, TX, USA). All tests were two-tailed with statistical significance set at p < 0.05. We obtained an exemption from the Human Investigations Committee before beginning the study. In this study, 332 patients underwent prophylactic femoral stabilization and 288 patients underwent operative fixation of a pathologic fracture of the femoral shaft or distal femur for a total of 620 patients (Table 1) . Patients undergoing prophylactic stabilization had higher BMI (28 6 8 kg/m 2 versus 25 6 11 kg/m 2 ; p = 0.001), whereas the fracture treatment group had a greater incidence of disseminated cancer (56% versus 44%; p = 0.003). There were no differences in terms of age, sex, or ASA class.
Results

Frequency of Adverse Events
In the 332 patients in the prophylactic stabilization group, 60 patients (18%) experienced any adverse event. Within that group, 47 patients (14%) experienced a major adverse event and 25 patients (8%) experienced a minor adverse event. The 30-day incidence of death was 7% (22 patients), and 32 patients (11%) were readmitted to a hospital. Among individual adverse events, the most common were readmission (11%), death (7%), venous thromboembolism (11 patients [3%]), pneumonia (11 patients [3%]), and return to the operating room (eight patients [2%]; Table 2 ).
In the 288 patients in the fracture treatment group, 77 patients (27%) experienced any adverse event. Of those, 65 (23%) experienced a major adverse event and 21 (7%) experienced a minor adverse event. The 30-day frequency of death was 13% (38 patients). Hospital readmissions occurred in 25 (11%) patients. Among individual adverse events, the most common were death (13%), readmission Table 3 ).
Discussion
Patients with metastatic disease affecting the femur may face considerable pain, disability, and the potential for pathologic fracture, which is associated with further complications [2, 4] . To help patients make informed decisions about their treatment options, it is essential to understand the potential complications that may arise from undergoing prophylactic surgical stabilization and the complications that may follow a pathologic fracture if surgery is not selected. We found that patients who undergo prophylactic stabilization experienced a lower incidence of perioperative blood transfusion after controlling for demographics, medical comorbidity, and disseminated cancer, whereas there were no differences in other outcomes.
The current study has several limitations. For both groups, the NSQIP database is limited to patients who underwent surgery. As such, it is not possible to characterize the incidence of adverse events in patients with metastatic disease involving the femur who elect not to have surgery (including how frequently the metastatic lesions went on to fracture), which could provide valuable information on how much of the complication rate is related to the surgical procedure versus the underlying disease. Because NSQIP's sampling practices do not yield a nationally representative sample, the current study also cannot be used to characterize the national incidence of either prophylactic stabilization or pathologic femur fractures. Another limitation is in the definition and consistency of the disseminated cancer variable. The variable is a creation of the NSQIP database and is not directly related to other established measures of cancer (eg, histologic grade or tumor staging); as such, its clinical relevance is not well characterized. Similarly, because NSQIP does not provide access to original patient records, it is impossible to audit the consistency of coding for this variable. Other than patient demographics, ASA class, and the disseminated cancer variable, NSQIP lacks detailed data concerning the severity of metastatic disease, the primary tumor, other treatment modalities (eg, chemotherapy or radiotherapy), and other variables that may be associated with adverse events, which may have limited the ability to thoroughly control for baseline differences between the groups. This also prevented the authors from reviewing patients' indications for surgery and determining whether they were consistent with established guidelines [7, 9] . Also, within the prophylactic stabilization group, it was not possible to distinguish whether the femoral shaft or distal femur was involved or identify the type of fixation used. Although the current study featured a relatively large patient population compared with other studies on metastatic long bone disease, it is still possible that the sample size and statistical power were not great enough to detect certain differences between groups, particularly after controlling for disseminated cancer. Finally, consistent with NSQIP practices, patients were only followed to postoperative day 30. Many patients with metastatic bone disease likely experience complications beyond this time, so the current study likely does not characterize the entire postoperative course for this population. Number equals number of patients experiencing adverse event; percent equals the percentage of patients experiencing adverse event. *variable only collected from 2011-2015, so only those patients included in the percentages; SSI = surgical site infection.
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The current study found that > 18% of patients who undergo prophylactic stabilization of the femur experience at least one adverse event within postoperative day 30; this includes 14% of patients who experience a major adverse event and nearly 7% who die during this period. This represents a high incidence of adverse events, comparable to geriatric hip fractures in orthopaedic surgery research [5] . This finding highlights the high morbidity and mortality faced by these patients, even before the occurrence of a pathologic fracture. Compared with the current study, Ward et al. [19] found a similar length of stay, discharge to a nonhome facility, and mortality rates in patients who underwent prophylactic stabilization, although this study included proximal femur metastases as well. However, they did not report on the occurrence of other postoperative complications. Kreul et al. [8] studied the outcomes of prophylactic femoral fixation and found a similar incidence of morbidities, although 96% of these involved the proximal femur rather than the shaft or distal femur.
In comparing the complication profile of prophylactic stabilization with treatment after a pathologic fracture, we found that patients treated with prophylactic stabilization experienced no difference in use of blood transfusions after controlling for patient demographics, ASA class, and disseminated cancer as defined in NSQIP [1] . Disseminated cancer was more prevalent in the fracture treatment group than in the prophylactic stabilization group, and accounting for this difference in physiologically disruptive cancers mitigated the difference between the groups that was seen when controlling for demographics and ASA class but not disseminated cancer. Given no difference in outcomes between the two groups, this suggests that existing treatment guidelines have identified a reasonable balance patient selection and timing of treatment. Prophylactic operative treatment does not add additional morbidity or mortality, and although those who experience a pathologic fracture, whether because their metastatic lesion was not detected or because conservative management was selected, fracture fixation and postoperative care are successful to the point that the fracture is not substantially worsening outcomes. Although this does not directly reflect on the efficacy of treatment guidelines for impending pathologic fracture, it suggests that the current guidelines achieve a reasonable balance in terms of postoperative morbidity and mortality. However, it is also possible that there is a false-negative finding related to the sample size and limited statistical power. Given that these findings seemed to trend toward a difference, a larger sample may demonstrate that there is a difference between the groups. Prior investigations have revealed mixed findings in terms of the differences between patients treated with prophylactic stabilization versus treatment of a pathologic femur fracture (Table 4) [8, 19] . Of note, Ward et al. [8] found increased blood loss in patients with pathologic fracture fixation versus prophylactic stabilization for all femur lesions, consistent with the current finding of increased perioperative transfusion use.
It is difficult to characterize how much of the complications were related to the surgery versus the underlying neoplasm, because this topic has received little attention. In studying pathologic fractures, Park et al. [14] found that patients with pathologic hip fractures secondary to multiple myeloma experienced an increased incidence of certain infections and acute kidney injury compared with patients with geriatric hip fractures unrelated to cancer; however, there were no differences in overall mortality, venous thromboembolisms, or other complications. The current study suggests that the presence of disseminated cancer was an important factor related to postoperative adverse events.
In the study sample, disseminated cancer was independently associated with death and increased hospital length of stay (see Appendix, Supplemental Digital Content 2), whereas it also posed as an important confounding variable with any adverse event and major adverse event. However, because there was no nonoperative control group, it is difficult to isolate the role of the neoplasm itself versus undergoing surgery of any sort. Future studies should attempt to follow patients with metastatic lesions of the femoral shaft or distal femur and characterize the adverse event profile in patients who undergo prophylactic operative stabilization versus those who elect observation. Ethical barriers would likely prevent a randomized controlled trial, and there may be limitations in terms of baseline medical differences between the two groups in an observational study [2] . Nevertheless, a prospective observational study comparing operative and conservative treatment, controlling for potential differences between groups, may help to characterize the role of surgical intervention versus disease course in adverse events. With a better understanding of the relative roles of underlying disease versus operative treatment in adverse events, investigators may be able to improve patient selection and postoperative care to improve outcomes for patients with metastatic lesions of the femur. Prophylactic surgical stabilization is performed in patients with metastatic lesions who are considered to have a high risk of impending pathologic fracture. Patients who undergo prophylactic stabilization have a relatively high incidence of adverse events, discharge to a facility, and mortality, which are likely related to both the surgical procedure and their underlying disease; orthopaedic oncologists should convey these risks to patients to inform treatment selection. After controlling for demographics and medical condition, patients who undergo prophylactic stabilization have a lower incidence of adverse events compared with those who sustain a pathologic fracture; there was no difference in the incidence of other adverse events between the two groups, although it may trend toward a lower incidence and decreased hospital length of stay for the prophylactic group. Given the differing incidence of disseminated cancer between the groups, the complications associated with advanced metastatic disease may overpower the advantages seen when comparing groups with less severe disease. The similar-to-improved perioperative complication profile of prophylactic stabilization, in conjunction with prior studies that have demonstrated good mechanical and functional outcomes [2, 17, 19] , supports the role of prophylactic surgical stabilization of impending femur fractures in appropriately selected patients. At the same time, no difference in outcomes between the two groups suggests that existing guidelines for patient selection and treatment have established a reasonable balance of morbidity between patients who undergo prophylactic stabilization and those who do not. Further investigation is needed to better characterize the roles of surgery versus underlying disease in terms of adverse events, which may enable more focused efforts to identify patients who may experience complications or tailor patient care to prevent adverse events. 
